Skip to main content

Diagnosis of pancreatic carcinoma: role of FDG PET.

Publication ,  Journal Article
Keogan, MT; Tyler, D; Clark, L; Branch, MS; McDermott, VG; DeLong, DM; Coleman, RE
Published in: AJR Am J Roentgenol
December 1998

OBJECTIVE: The purpose of this study was to investigate the role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in differentiating benign from malignant disease in patients with possible pancreatic malignancy. SUBJECTS AND METHODS: All patients with a possible diagnosis of pancreatic carcinoma based on CT or ERCP findings were eligible for inclusion in this prospective study. PET imaging of the abdomen was performed in 37 patients and was interpreted as positive if FDG activity in the pancreas exceeded background activity and as negative if activity was less than or equal to background activity. Semiquantitative analysis was performed by calculating a standardized uptake ratio. Studies were reviewed independently by two radiologists, and results were correlated with biopsy results and with CT and ERCP findings. Sensitivity and specificity of FDG PET for revealing pancreatic malignancy was determined. RESULTS: FDG activity in the pancreas was increased in 24 patients, and adenocarcinoma was diagnosed in 22 of these patients (92%). Two patients (8%) with increased activity had benign disease, including one patient with chronic pancreatitis who showed no evidence of tumor at laparotomy and one patient with a mucinous cystic tumor who showed no malignant features at laparotomy. FDG uptake was low or normal in 13 patients, 10 of whom (77%) had benign disease. FDG uptake was also low in three patients with adenocarcinoma, whose tumor size ranged from 2 to 4 cm in diameter. The mean standardized uptake ratio value for malignant disease was 5.1 (range, 1.0-10.1) and for benign disease was 1.9 (range, 0.0-5.8) (p < .001). The sensitivity of FDG PET for revealing malignant disease in the pancreas was 88% and the specificity was 83%. CONCLUSION: FDG PET is a sensitive and specific noninvasive technique for the diagnosis of pancreatic malignancy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AJR Am J Roentgenol

DOI

ISSN

0361-803X

Publication Date

December 1998

Volume

171

Issue

6

Start / End Page

1565 / 1570

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Sensitivity and Specificity
  • Radiopharmaceuticals
  • Prospective Studies
  • Pancreatic Neoplasms
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Humans
  • Fluorodeoxyglucose F18
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Keogan, M. T., Tyler, D., Clark, L., Branch, M. S., McDermott, V. G., DeLong, D. M., & Coleman, R. E. (1998). Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol, 171(6), 1565–1570. https://doi.org/10.2214/ajr.171.6.9843289
Keogan, M. T., D. Tyler, L. Clark, M. S. Branch, V. G. McDermott, D. M. DeLong, and R. E. Coleman. “Diagnosis of pancreatic carcinoma: role of FDG PET.AJR Am J Roentgenol 171, no. 6 (December 1998): 1565–70. https://doi.org/10.2214/ajr.171.6.9843289.
Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol. 1998 Dec;171(6):1565–70.
Keogan, M. T., et al. “Diagnosis of pancreatic carcinoma: role of FDG PET.AJR Am J Roentgenol, vol. 171, no. 6, Dec. 1998, pp. 1565–70. Pubmed, doi:10.2214/ajr.171.6.9843289.
Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, Coleman RE. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol. 1998 Dec;171(6):1565–1570.

Published In

AJR Am J Roentgenol

DOI

ISSN

0361-803X

Publication Date

December 1998

Volume

171

Issue

6

Start / End Page

1565 / 1570

Location

United States

Related Subject Headings

  • Tomography, Emission-Computed
  • Sensitivity and Specificity
  • Radiopharmaceuticals
  • Prospective Studies
  • Pancreatic Neoplasms
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Humans
  • Fluorodeoxyglucose F18